Home » Clinical Trials » STOPFOP: Saracatinib Trial TO Prevent FOP

Research area:

Rare disease

Disease:

Fibrodysplasia ossificans progressiva

Intervention:

Therapeutics – small molecules

Phase:

Phase II

STOPFOP: Saracatinib Trial TO Prevent FOP

Intervention

Therapeutics – small molecules

Funding awarded to

University of Oxford

Public registration details (where available)

NCT04307953

Planned trial start and expected end date

August 2020 to May 2025

Related news

Dementia Consortium funds Manchester based team targeting immune system in search for new dementia treatments

Read more: Dementia Consortium funds Manchester based team targeting immune system in search for new dementia treatments

MRC Technology invests £7 million to expand its diagnostics research capability in Scotland

Read more: MRC Technology invests £7 million to expand its diagnostics research capability in Scotland

UK Drug Discovery Consortium symposium

Read more: UK Drug Discovery Consortium symposium